These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11346151)

  • 1. Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"?
    Giannini E; Testa R
    Dig Liver Dis; 2001 Mar; 33(2):202-3. PubMed ID: 11346151
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?
    Puoti C; Castellacci R; Montagnese F
    Dig Liver Dis; 2000 Oct; 32(7):634-43. PubMed ID: 11142566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?
    Perez RM; Ferreira AS; Medina-Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
    Clin Transplant; 2005 Oct; 19(5):622-5. PubMed ID: 16146553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subjects positive for hepatitis C virus RNA with normal aminotransferase levels, a "trompe l'oeil" clinical picture?
    Morisco F; Leone D; Tuccillo C; Iasevoli P; Sessa G; De Luise G; De Dominicis R; Caporaso N
    Dig Liver Dis; 2000 Oct; 32(7):598-602. PubMed ID: 11142558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue.
    Bonino F; Colombatto P; Brunetto MR
    Dig Liver Dis; 2000 Oct; 32(7):603-4. PubMed ID: 11142559
    [No Abstract]   [Full Text] [Related]  

  • 6. [HCV-RNA test in hepatitis C virus infection--a systematic review].
    Takedai M; Takatani A; Funato T; Ino K; Nakayama T; Nomura F; Miyachi H; Noboru T; Ueda K
    Rinsho Byori; 2008 Oct; 56(10):868-76. PubMed ID: 19068783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection.
    Murray KF; Finn LS; Taylor SL; Seidel KD; Larson AM
    J Pediatr Gastroenterol Nutr; 2005 Nov; 41(5):634-8. PubMed ID: 16254522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Rebound" phenomenon of hepatitis C viremia after interferon therapy in "relapsed" patients with chronic hepatitis C.
    Hanada H; Hino K; Fujii K; Okazaki M; Okita K
    J Gastroenterol; 1995 Jun; 30(3):347-50. PubMed ID: 7544188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.
    Uto H; Kurogi J; Takahama Y; Kusumoto K; Hayashi K; Ido A; Kohara M; Stuver SO; Moriuchi A; Hasegawa S; Oketani M; Tsubouchi H
    J Gastroenterol; 2007 Aug; 42(8):673-80. PubMed ID: 17701131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels.
    Nutt AK; Hassan HA; Lindsey J; Lamps LW; Raufman JP
    Am J Med; 2000 Jul; 109(1):62-4. PubMed ID: 10936480
    [No Abstract]   [Full Text] [Related]  

  • 11. More sensitive hepatitis C virus RNA detection: what for?
    Pawlotsky JM
    J Hepatol; 2010 Jun; 52(6):783-5. PubMed ID: 20385426
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of diagnostic testing for managing hepatitis C virus infection.
    Ferreira-Gonzalez A; Shiffman ML
    Semin Liver Dis; 2004; 24 Suppl 2():9-18. PubMed ID: 15346241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with chronic hepatitis C and normal transaminases.
    Pereira HM; Cavalheiro Nde P; Tengan FM; Melo CE; Mello ES; Barone AA
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):247-51. PubMed ID: 16302106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection.
    Haydon GH; Jarvis LM; Blair CS; Simmonds P; Harrison DJ; Simpson KJ; Hayes PC
    Gut; 1998 Apr; 42(4):570-5. PubMed ID: 9616323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
    Prati D; Shiffman ML; Diago M; Gane E; Rajender Reddy K; Pockros P; Farci P; O'Brien CB; Lardelli P; Blotner S; Zeuzem S
    J Hepatol; 2006 Apr; 44(4):679-85. PubMed ID: 16487620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
    Shiffman ML; Diago M; Tran A; Pockros P; Reindollar R; Prati D; Rodríguez-Torres M; Lardelli P; Blotner S; Zeuzem S
    Clin Gastroenterol Hepatol; 2006 May; 4(5):645-52. PubMed ID: 16630770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C.
    Mihm U; Hofmann WP; Kronenberger B; Wagner Mv; Zeuzem S; Sarrazin C
    J Hepatol; 2005 Apr; 42(4):605-6. PubMed ID: 15763349
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Serfaty L
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B202-5. PubMed ID: 12180289
    [No Abstract]   [Full Text] [Related]  

  • 19. [Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
    MMW Fortschr Med; 2004 May; 146(19):64. PubMed ID: 15357490
    [No Abstract]   [Full Text] [Related]  

  • 20. Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases.
    Maida I; Soriano V; Barreiro P; Rivas P; Labarga P; Núñez M
    AIDS Res Hum Retroviruses; 2007 Jun; 23(6):801-4. PubMed ID: 17604543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.